Discrepancies between biomarkers of primary breast cancer and subsequent brain metastases: an international multicenter study
Autor: | Peter Bult, Caroline Weltens, Lorenzo Livi, B. Vieites, D. Limon, Prantesh Jain, Yazid Belkacemi, V.L. Chiang, N. Kurman, Philip Poortmans, Kevin Ko, Nicole L. Simone, James B. Yu, P. Navarria, Timothy M. Zagar, J. Lopez-Guerra, Brigitta G. Baumert, Orit Kaidar-Person, Icro Meattini, I. Kindts, R. Steffens |
---|---|
Rok vydání: | 2018 |
Předmět: |
Adult
0301 basic medicine Oncology Cancer Research medicine.medical_specialty Receptor Status Receptor ErbB-2 Estrogen receptor Breast Neoplasms 03 medical and health sciences All institutes and research themes of the Radboud University Medical Center 0302 clinical medicine Breast cancer Internal medicine Progesterone receptor Biomarkers Tumor medicine Humans Neoplasm Metastasis skin and connective tissue diseases Receptor In Situ Hybridization Fluorescence Aged Aged 80 and over Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17] medicine.diagnostic_test Brain Neoplasms business.industry Estrogen Receptor alpha Middle Aged medicine.disease Primary tumor Women's cancers Radboud Institute for Health Sciences [Radboudumc 17] Gene Expression Regulation Neoplastic 030104 developmental biology 030220 oncology & carcinogenesis Female Receptors Progesterone business Estrogen receptor alpha Fluorescence in situ hybridization |
Zdroj: | Breast Cancer Research and Treatment, 167, 2, pp. 479-483 Breast Cancer Research and Treatment, 167, 479-483 |
ISSN: | 0167-6806 |
Popis: | Discordances between the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), expression between primary breast tumors and their subsequent brain metastases (BM) were investigated in breast cancer patients. We collected retrospective data from 11 institutions in 8 countries in a predefined-standardized format. Receptor status (positive or negative) was determined according to institutional guidelines (immunohistochemically and/or fluorescence in situ hybridization). The study was subject to each institution’s ethical research committee. A total of 167 breast cancer patients with BM were included. 25 patients out of 129 with a complete receptor information from both primary tumor and BM (ER, PR, HER2) available, had a change in receptor status: 7 of 26 (27%) ER/PR-positive/HER2-negative primaries (3 gained HER2; 4 lost expression of ER/PR); 10 of 31 (32%) ER/PR-positive/HER2-positive primaries (4 lost ER/PR only; 3 lost HER2 only; 3 lost both ER/PR and HER2); one of 33 (3%) ER/PR-negative receptor/HER2-positive primaries (gained ER); and 7 of 39 (18%) triple-negative primaries (5 gained ER/PR and 2 gained HER2). The majority of breast cancer patients with BM in this series had primary HER2-enriched tumors, followed by those with a triple-negative profile. One out of 5 patients had a receptor discrepancy between the primary tumor and subsequent BM. Therefore, we advise receptor status assessment of BM in all breast cancer patients with available histology as it may have significant implications for therapy. |
Databáze: | OpenAIRE |
Externí odkaz: |